ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedic
How this was made
The 30-second read
Why it matters
The Phase 1b results provide the first robust clinical evidence for efficacy in the underserved EGFR PACC‑mutant NSCLC subgroup, potentially positioning firmonertinib as a first‑line option.
Market read
First‑time disclosure of compelling early‑stage data for a novel lung‑cancer therapy, likely to influence AVBP's stock and related oncology biotech peers.
What to watch
Regulatory timelines and reimbursement landscape for a novel EGFR PACC indication could temper upside despite strong early data.
Background
ArriVent BioPharma (NASDAQ: AVBP) is a clinical‑stage company developing firmonertinib, an oral EGFR inhibitor with breakthrough and orphan designations in the US.
Ticker impact
ArriVent BioPharma disclosed Phase 1b trial results for firmonertinib in EGFR PACC‑mutant NSCLC, showing high response rates and durable progression‑free survival.
likely upward pressure as market prices in the robust response and PFS data
The disclosed ORR of 43‑68% and median PFS of 11‑16 months are materially better than existing therapies, representing a meaningful clinical milestone.
Market effects
Positive data could lift peer biotech stocks focused on EGFR‑targeted therapies and broader oncology R&D sector.
US biotech market may see modest gains; Chinese market impact limited as firmonertinib already approved there.
Adds to global pipeline confidence for targeted lung‑cancer treatments, potentially influencing cross‑border collaborations.
Counterpoint
Investors may remain cautious until Phase 3 data confirm durability and safety, given historical attrition rates in oncology trials.
Key entities
- companyArriVent BioPharma, Inc.
Developer of firmonertinib and sponsor of the ALPACCA Phase 3 trial.
- drugFirmonertinib
Oral, brain‑penetrant EGFR inhibitor targeting PACC and exon 20 insertion mutations.
